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Hawk Kim,1 Kyoo-Hyung Lee,2 Sung-Soo Yoon,3 Sang Kyun Sohn,4 Young Don Joo,5
Sung Hyun Kim,6 Byung Soo Kim,7 Jung Hye Choi,8 Jae Youg Kwak,9 Myung Soo Hyun,10
Sung Hwa Bae,11 Ho Jin Shin,12 Jong Ho Won,13 Sukjoong Oh,14 Won Sik Lee,15
Jae-Hoo Park,1 Chul Won Jung,16 on behalf of The Korean Society
of Blood and Marrow TransplantationAlthough younger age is associated with favorable prognosis in adults undergoing allogeneic hematopoietic
stem cell transplantation (allo-HSCT) for aplastic anemia (AA), other pretransplantation factors may be
more important than age. We retrospectively analyzed the impact of older age on transplantation outcomes
and survival in a total of 225 adult patients with AA who underwent allo-HSCT: 57 patients .40 years old
(older patient group [OPG]) and 168 patients #40 years old (younger patient group [YPG]). Age at allo-
HSCT #40 years, time from diagnosis to allo-HSCT #6 months, and matched related donor (MRD)
were favorable prognostic factors in all study patients. Risk analysis of survival in the OPG showed that
age .50 years was the only poor prognostic factor. Survival did not differ significantly between the YPG
and patients\50 years old in the OPG. In conclusion, patients between the ages of 41 and 50 years with
severe AA and MRDs should undergo allo-HSCT as early as possible to optimize survival.
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Younger age is associated with favorable prognosis
for adults undergoing allogeneic hematopoietic stem
cell transplantation (allo-HSCT) for severe aplastic
anemia (AA). Most guidelines recommend that only
patients \40 years old with suitable HLA-identical
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Advances in supportive care and transplantation
outcomes after allo-HSCT, both from matched unre-
lated donors (MUDs) and HLA-identical sibling do-
nors, have resulted in better survival outcomes after
early transplantation [4]. Therefore, delaying allo-
HSCT in older patients after immunosuppressive
therapy (IST) failure can result in poor survival.
Patients age .30 years receiving a fludarabine-based
preparative regimen showed statistically significant
improvements in survival outcomes after HLA-
identical sibling allo-HSCT [5]. In addition, survival
after allo-HSCT from MUDs has improved in recent
years [4]. These findings have suggested that early allo-
HSCT may be beneficial, even in older patients.
Older patients previously thought unsuitable for
allo-HSCT are now undergoing allo-HSCT after re-
duced intensity conditioning regimens and improved
supportive care. Patients 40 to 50 and even 50 to 60
years old with good performance status who failed
IST can now be considered for allo-HSCT from
MUDs [2,3]. However, the results of allo-HSCT in
older patients with severe AA and factors associated
with poor survival in these patients have not been fully
determined. We, therefore, retrospectively analyzed
the impact of age on the survival and transplantation
outcomes in adults undergoing allo-HSCT for AA.
Biol Blood Marrow Transplant 18:1500-1508, 2012 1501Allogeneic HSCT for .40 Year Olds with Acquired Aplastic AnemiaWe also assessed risk factors for poor survival among
patients .40 years old.PATIENTS AND METHODS
Patient Eligibility
Patients diagnosed with severe acquired aplastic
anemia (SAAA), who were .15 years old at the time
of allo-HSCT and had undergone allo-HSCT from
a matched related donor (MRD) or alternative donor
(AD), regardless of IST history, were eligible. All eligi-
ble patients were fully informed of the nature and pur-
pose of this study, and all provided written informed
consent before enrollment. All patients fully under-
stood that they were entitled to exit the study without
any negative consequences. Exclusion criteria included
the presence of congenital aplasia, including Fanconi
anemia, Diamond-Blackfan syndrome, or congenital
dyskeratosis; or hypoplastic myelodysplastic syn-
drome. Data were collected from patients with pure
red cell aplasia and paroxysmal nocturnal hemoglobin-
uria during the protocol design phase, but such
patients were not included in the final analyses.
Patients were divided into 2 groups by age at allo-
HSCT, with the younger patient group (YPG) being
#40 years and the older patient group (OPG) being
.40 years old.
Data Collection
The protocol for this retrospective multicenter
study was submitted to and approved by the Korean
Society of Blood andMarrowTransplantation Clinical
StudyCommittee (approval no. KSBMT07-02) and by
the institutional review board of each participating in-
stitution. Case report form questionnaires defining
items to be evaluated were provided to institutional in-
vestigators. If case report form questionnaires were
insufficient or incomplete, principal investigators
queried institutional collaborators to obtain the miss-
ing information. Data collection started in 2007 for
6 months, with 1 institution adding data from 2009.
Evaluation Criteria
The principal outcome of this study was survival
after allo-HSCT in the OPG and YPG. The hemato-
logical response to IST was assessed during the first
6 months after treatment. Responses to IST were re-
quired to be sustained without transfusion, or by
administration of growth factors, and were con-
firmed using a minimum of 2 observations at least 4
weeks apart. A complete response was defined as
transfusion-independence plus all cell lines tested be-
ing normal for age and gender (SAAA criteria). A partial
response (PR)was defined as transfusion-independence
but the SAAA criteria had not beenmet. A nonresponsewas defined as transfusion-dependence or when the pe-
ripheral blood count criteria for PR had not been at-
tained. Relapse after IST was defined as a decrease in
any peripheral blood cell count to\50%of themedian
sustained count observed during the response phase, or
as dependence on transfusion.
ABO blood type incompatibility between donors
and recipients was classified as major (ie, the recipient
had anti-A and/or anti-B Abs capable of reacting with
antigens on donor red cells), minor (ie, the donor had
anti-A and/or anti-B Abs capable of reacting with anti-
gens on recipient red cells and tissues), mixed (ie,
a transplantation involving a group B donor and
a group A recipient, or vice versa), or compatible. Neu-
trophil engraftment was defined as the first of 3 con-
secutive days on which recipient absolute neutrophil
count (ANC) was .0.5  109/L after a nadir, and
platelet engraftment was defined as the first of 7 con-
secutive days on which the unsupported platelet count
was.20 109/L. Primary graft failure (or early rejec-
tion) was defined as a peripheral ANC\0.5  109/L
persisting formore than 21 days after allo-HSCT. Sec-
ondary graft failure was defined as marrow hypoplasia
after engraftment, with a requirement for frequent
(more than once weekly) platelet transfusion, or an
ANC \0.5  109/L, but without growth factor re-
quirements extending beyond day 60.
Acute and chronic graft-versus-host disease
(aGVHDand cGVHD)were diagnosed and graded ac-
cording to the Seattle criteria [6,7], and sinusoidal
obstruction syndrome (SOS) was diagnosed using
McDonald’s guidelines [8]. Performance status was
graded by Eastern Cooperative Oncology Group
(ECOG) performance scoring. Relapse was defined as
reacquisition of transfusion-dependence or fulfillment
of severe/very severe criteria after full engraftment.Definitions of Survival Times
The starting point for determination of survival
parameters was the first day of stem cell infusion.
Relapse-free survival, measured only in patients show-
ing successful engraftment and not requiring regular
transfusions, was defined as the time from commence-
ment of a conditioning regimen to the date on which
the patient was first recorded with disease relapse, or
the date of death. Patients without relapse or death
were censored at the date of last follow-up. Time to re-
lapse was measured from the day of stem cell infusion
to the date on which a patient withdrew from the study
because of adverse events, progressive disease, insuffi-
cient therapeutic response, death, failure to return for
follow-up, refusal of treatment, refusal to cooperate, or
withdrawal of consent. If none of these events oc-
curred, patients were censored on the date of last
follow-up. Overall survival was measured from the
time of commencement of a conditioning regimen to
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was known to be alive (this constituted censoring).Statistical Analysis
All analyses were performed on an intention-to-
treat basis. The chi-squared test was used to compare
categorical variables, and the t test was used to com-
pare continuous variables between any 2 groups.
Times to engraftment, aGVHD, and cGVHD were
estimated using the cumulative incidence function,
and differences were compared using Gray’s test [9].
Survival curves were computed according to the
Kaplan-Meier method, and differences in survival
were compared by the log-rank test. A Cox propor-
tional hazards model was used to determine the effects
on survival of various prognostic factors, including
age, donor/recipient gender matching, number of cells
transfused, use of irradiated blood products, time from
diagnosis to allo-HSCT, stem cell source, dose of irra-
diation, HLA matching, method of immune suppres-
sion used to prevent GVHD, prior IST, and use of
antithymocyte globulin (ATG). All variables were di-
chotomized and converted into categorical classes.
Variables considered in multivariate analysis included
patient age and all prognostic factors with P values\
.10 in univariate analysis. Differences were assessed us-
ing a 2-sided test at the P 5 .05 level of significance.
We used the R package (cmprsk) to analyze cumulative
incidence, and SPSS version 17 (SPSS, Inc., Chicago,
IL) for all other statistical analyses.RESULTS
Patients
Our initial patient population consisted of 234
consecutive patients with AA who underwent allo-
HSCT between 1995 and 2008 at 15 of the 40 trans-
plantation centers in Korea, including most major
centers. After excluding 1 patient with pure red cell
aplasia and 8 with paroxysmal nocturnal hemoglobin-
uria, our patient population consisted of 225 adults
with AA who underwent allo-HSCT. Median follow-
up time for survivors was 36.0 months (range, 1.41-
125.72 months). Of these patients, 117 were men
(52.0%) and their median age at the time of allo-
HSCT was 31.2 years (range, 15-63 years). We deter-
mined that 103 patients (45.8%) had received prior
IST, including 66 (29.3%) who were treated with
ATG or antilymphocyte globulin (ALG); of the latter,
only 17 (16.5%) responded, with complete response
evident in 2 and PR in 15. ABO blood-type matching
was compatible in 110 (53.7%) donor–recipient pairs.
Stem cell sources included bone marrow (BM) only in
172 patients (76.4%), peripheral blood only in 46 pa-
tients (20.4%), and both in 7 patients (3.1%); 185 pairs(82.2%) were fully HLA-matched. Of the 225 donors,
162 (72.0%) were related and 63 (28.0%) were unre-
lated; 152 (67.6%) donors were MRDs and 73
(32.4%) were ADs. Classical cyclophosphamide (200
mg/kg)-ATG/ALG (Cy-ATG/ALG) was the most
common conditioning regimen used in 126 patients
(56.0%). Other conditioning regimens included
fludarabine-based regimen (n 5 70; 31.1%) and total
body irradiation (TBI)-based regimen (n 5 24;
10.7%). Drugs used for GVHD prophylaxis were cy-
closporine (93.8%), methotrexate (68.0%), predniso-
lone (7.1%), tacrolimus (5.3%), and mycophenolate
mofetil (1.8%).
The YPG and OPG consisted of 168 and 57 pa-
tients, respectively, with median ages of 25 years
(range, 20-39.9 years) and 45.7 years (range, 40.1-
63.6 years), respectively. Gender distribution (P 5
.614), prior IST (P 5 .854), packed red cell (PRC)
transfusion (P 5 .671), allo-HSCT from MSD (P 5
.386), HLA full matching (P 5 .241), compatible
ABO blood-typing (P 5 .592), classical Cy-ATG
(P 5 .643), TBI as a conditioning regimen (P 5
.410), ATG/ALG as a conditioning regimen (P 5
.275), BM as a stem cell source (P 5 .377), amount
of red cell transfusion before allo-HSCT (P 5 .671),
and infused CD341 cells (P5 .473) were all compara-
ble in the 2 groups (Table 1). Amounts of platelet
transfusion before allo-HSCT (P 5 .036), and female
donor-to-male recipient transplantation (P 5 .089)
tended to be more frequent in the OPG.Prognostic Factors Affecting Overall Survival
in All Patients
Univariate analysis of all 225 recipients showed
that no prior IST (P 5 .005), age #40 years at
allo-HSCT (P 5 .007), time from diagnosis to allo-
HSCT #6 months (P 5 .008), sibling donor (P 5
.002), and HLA full match (P 5 .019) were significant
favorable predictors of overall survival, with ABO
compatibility (P5 .055) and prior platelet concentrate
(PC) transfusion amount (P 5 .063) being marginally
significant (Table 2). In contrast, gender (P 5 .640),
female donor-to-male recipient (P 5 .499), ECOG
performance status at allo-HSCT (P 5 .948), prior
PRC transfusion amount (P5 .396), TBI conditioning
(P 5 .525), ATG/ALG conditioning (P 5 .628),
Cy-ATG/ALG conditioning (P 5 .585), BM as a
stem cell source (P 5 .224), and infused CD34 cells
(P 5 .305) were not significant.
In multivariate analysis, only age#40 years at allo-
HSCT (hazard ratio [HR] 5 0.403; 95% confidence
interval [CI] 5 0.227-0.715; P 5 .002), time from
diagnosis to allo-HSCT #6 months (HR 5 0.464;
95% CI 5 0.247-0.872; P 5 .017), and sibling donor
(HR 5 0.524; 95% CI 5 0.294-0.933; P 5 .028)
were favorable prognostic factors (Table 3).
Table 1. Characteristics of Patients
Characteristics YPG (#40 years) OPG (>40 years) P value
Gender, male/female, n (%) 88 (52.4)/80 (47.6) 29 (50.9)/28 (49.1) .844
Prior IST 78 (46.4) 31 (56.4) .737
Allo-HSCT from MRD 112 (66.7) 43 (78.2) .625
HLA full match 136 (81.0) 49 (86.0) .392
Female-to-male allo-HSCT 25 (14.9) 14 (24.6) .095
Compatible ABO blood-typing 81 (48.2) 29 (50.9) .728
Classical Cy (200 mg/kg)-ATG conditioning 96 (57.1) 30 (52.6) .643
Fludarabine as a conditioning regimen 48 (28.6) 22 (38.6) .186
TBI as a conditioning regimen 17 (10.1) 7 (12.5) .648
ATG/ALG as a conditioning regimen 132 (78.6) 41 (71.9) .304
BM as a stem cell source 137 (81.5) 42 (73.7) .203
Median (range)
Age, yr 27 (15-39.5) 45.7 (40.1-63.6) <.001
Units of PRC transfusion 12 (0-114) 12 (3-79) .451
Units of PC transfusion 86 (0-812) 96 (8-574) .036
Infused CD34+ cells,  106/kg 3.8 (0.11-28) 3.9 (0.2-30.2) .415
YPG indicates younger patient group; OPG, older patient group; IST, immune suppression therapy; allo-HSCT, allogeneic hematopoietic stem cell trans-
plantation; MRD,matched related donor; Cy, cyclophosphamide; ATG, antithymocyte globulin; TBI, total body irradiation; ALG, antilymphocyte globulin;
BM, bone marrow; PRC, packed red cell; PC, platelet concentrate.
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YPG and OPG
Most transplantation outcomes were comparable
in the YPG and OPG (Table 4), including rates of en-
graftment failure (P5 .972), SOS (P5 .582), aGVHD
(P5 .670), cGVHD (P5 .828), secondary graft failure
after HSCT (P 5 .756), and time to platelet engraft-
ment (P5 .770; Figure 1A). However, time to neutro-
phil engraftment was significantly faster in the OPG
(P 5 .009; Figure 1B). Causes of death were similar
in the 2 groups (P 5 .593). The most common cause
of death was infection (51.3% in the YPG and 54.5%
in the OPG; Table 4), followed by GVHD. Death
from engraftment failure was more frequent in the
YPG (15.4%) than in the OPG (4.5%).
Factors Prognostic for Survival in the OPG
Univariate analysis showed that age at allo-HSCT
40 to 50 versus.50 years (5 year survival rate [5YSR],Table 2. Univariate Analysis on Survival
Factor No. of p
Female versus male 117 ver
No prior IST versus prior IST 122 ver
Age at allo-HSCT #40 yr versus >40 yr 168 ver
Time from Dx to allo-HSCT #6 mo versus >6 mo 107 ver
Sibling donor versus others 162 ver
ABO compatible versus incompatible 95 versu
HLA full match versus mismatch 185 ver
Others versus female donor-to-male recipient 186 ver
ECOG performance status at allo-HSCT; >1 versus #1 33 versu
Prior PRC transfusion #12 units versus >12 units 160 ver
Prior PC transfusion #86 units versus >86 units 149 ver
Conditioning without versus with TBI 24 versu
Conditioning with versus without ATG/ALG 173 ver
Cy-ATG/ALG conditioning versus other 170 ver
BM as a stem cell source versus others 179 ver
Infused CD34 infusion >3 versus #3 (106/kg) 144 ver
IST indicates immune suppression therapy; allo-HSCT, allogeneic hematopoiet
Oncology Group; PRC, packed red cell; PC, platelet concentrate; TBI, total bo
ulin; Cy, cyclophosphamide; BM, bone marrow.76.6% versus 55.9%; P 5 .007), and HLA full match-
ing versus mismatch (5YSR, 60.0% versus 22.5%; P5
.023) were significantly prognostic for survival in the
OPG (Table 5). On multivariate analysis, however,
age #50 years (HR 5 0.307; 95% CI 5 0.126-0.748;
P5 .009) was the only favorable factor for overall sur-
vival. Prior IST (HR5 0.664; 95% CI5 0.269-1.642;
P 5 .376), time from diagnosis to allo-HSCT (HR 5
0.563; 95% CI 5 0.208-1.521; P 5 .257), and HLA
full matching (HR 5 0.472; 95% CI 5 0.156-1.426;
P 5 .183) were not significant.Overall Survival
Overall survival was significantly longer in the
YPG than in the OPG (5YSR, 75.0% versus 55.9%;
P 5 .007; Figure 2A). Moreover, overall survival was
significantly longer for patients age 40 to 50 years
than in those age .50 years (5YSR, 67.9% versus
0%; P 5 .016; Figure 2B). For patients .50 yearsatients 5-year survival rate (%) P value
sus 108 74.0 versus 67.7 .640
sus 103 77.4 versus 61.9 .005
sus 57 76.6 versus 55.9 .007
sus 118 78.7 versus 62.8 .008
sus 63 75.6 versus 56.2 .002
s 110 75.9 versus 59.3 .055
sus 40 73.1 versus 55.9 .019
sus 39 71.8 versus 63.1 .499
s 192 71.8 versus 70.0 .948
sus 65 71.9 versus 65.9 .396
sus 76 75.3 versus 58.7 .063
s 201 70.9 versus 65.0 .525
sus 52 71.6 versus 65.5 .628
sus 55 71.6 versus 65.6 .585
sus 46 72.9 versus 51.6 .224
sus 81 73.3 versus 65.6 .305
ic stem cell transplantation; Dx, diagnosis; ECOG, Eastern Cooperative
dy irradiation; ATG, antithymocyte globulin; ALG, antilymphocyte glob-
Table 3. Multivariate Analysis on Survival
Factor HR 95% CI P value
No prior IST versus prior IST 0.786 0.401-1.539 .482
Age at allo-HSCT #40 yr versus >40 yr 0.403 0.227-0.715 .002
Time from Dx to allo-HSCT #6 mo versus >6 mo 0.464 0.247-0.872 .017
Sibling donor versus others 0.524 0.294-0.933 .028
ABO compatible versus incompatible 0.684 0.392-1.194 .182
HLA full match versus mismatch 0.748 0.353-1.587 .450
Prior PC transfusion #86 units versus >86 units 0.676 0.382-1.194 .177
HR indicates hazard ratio; CI, confidence interval; IST, immune suppression therapy; allo-HSCT, allogeneic hematopoietic stem cell transplantation; Dx,
diagnosis; PC, platelet concentrate.
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4.3 months (95% CI, 0.0-29.9 months). Overall sur-
vival, however, was similar in YPG patients and those
in the OPG who were\50 years old (5YSR, 75.0%
versus 67.9%; P5 .282; Figure 3A), in patients in these
groups who underwent transplantation from MRDs
(5YSR, 82.5% versus 70.7%; P 5 .115; Figure 3B),
and in patients who underwent early transplantation
(\6 months from diagnosis to transplantation; 5YSR,
84.8% versus 79.1%; P 5 .361; Figure 3C). Overall
survival was also similar in YPG patients and those in
the OPG who were\50 years old from AD (5YSR,
60.1% versus 55.6%; P 5 .835), and in patients
who underwent late transplantation ($6 months
from diagnosis to transplantation; 5YSR, 67.1% versus
70.6%; P 5 .361).
In the OPG, the 5YSR was higher after transplan-
tation from MRD than from AD, but the difference
was not statistically significant (60.1% versus 45.2%;
P 5 .165). When we compared overall survival in
YPG patients who underwent allo-HSCT .6 months
from diagnosis with that in OPG patients who under-
went allo-HSCT#6months from diagnosis, we found
that 5YSR were almost similar (67.1% versus 62.2%;Table 4. Transplantation Outcomes between YPG versus OPG
Characteristics YPG (#40 years
Engraftment failure, n (%)
Any 35 (20.8)
Neutrophil 16 (9.5)
Platelet 23 (13.7)
SOS, n (%) 13 (7.7)
aGVHD, n (%) 40 (23.8)
cGVHD, n (%) 36 (21.4)
Extensive cGVHD, n (%) 15 (8.9)
Secondary graft failure after HSCT, n (%) 10 (6.0)
Causes of death n 5 39
Infection, n (%) 20 (51.3)
GVHD, n (%) 7 (17.9)
Engraftment failure, n (%) 6 (15.4)
Hemorrhage 2 (5.1)
Cum
Time to ANC >500/mL, d 17 (8-32)
Time to platelet >20K/mL, d 21 (5-423)
Time to aGVHD, d 30.5 (0-165)
Time to cGVHD, mo 4.4 (2.2-23.7)
YPG indicates younger patients group; OPG, older patients group; SOS, sinu
cGVHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell tra
*Calculated by Gray test.P 5 .905; Figure 4A). Moreover, survival rates were
similar in YPG patients who underwent allo-HSCT
from an AD and OPG patients who underwent
allo-HSCT from a sibling donor (60.1% versus
60.1%; P 5 .723; Figure 4B).DISCUSSION
Patients\40 years old with an HLA-identical sib-
ling donor should undergo allo-HSCT before IST,
whereas allo-HSCT from MUDs in older patients
can be attempted after IST failure. It is unclear, how-
ever, whether allo-HSCT should be delayed in pa-
tients age .40 years with suitable HLA-identical
sibling donors, especially because early transplantation
has been associated with better survival outcomes after
allo-HSCT in patients with AA [4,10].
Older age has shown negative impacts on platelet
recovery, incidence of GVHD, and mortality after
allo-HSCT [11]. More recently, however, allo-
HSCT outcomes have improved, although IST out-
comes have not [1,12]. Our univariate analyses
showed that factors significantly associated with
patient survival included no prior IST (P 5 .005), age) OPG (>40 years) P value
12 (21.1) .972
4 (7.0) .566
11 (19.3) .307
6 (10.5) .582
12 (21.1) .670
13 (22.8) .828
4 (7.0) .788
4 (7.0) .756
n 5 22 .593
12 (54.5)
4 (18.2)
1 (4.5)
2 (9.1)
ulative incidents, median (range)
16 (9-23) .009*
19 (10-122) .770*
22.5 (8-108) .726*
4.8 (2-12) .483*
soidal obstruction syndrome; aGVHD, acute graft-versus-host disease;
nsplantation; ANC, absolute neutrophil count.
Figure 1. Cumulative incidence of platelet (A) and neutrophil engraftment (B).
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sis to allo-HSCT#6 months (P5 .008), sibling donor
(P5 .002), and HLA full match (P5 .019). Multivari-
ate analysis, however, showed that only age #40 years
at allo-HSCT (P 5 .002), time from diagnosis to
allo-HSCT #6 months (P 5 .017), and sibling donor
(P5 .028) were favorable prognostic factors, confirm-
ing that age.40 years was significantly associated with
poor survival outcomes, but also showing that delayed
allo-HSCT was an unfavorable risk factor. When we
analyzed outcomes in our OPG, however, we found
that age.50 years was associated with poor prognosis,
whereas age 40 to 50 years was associated with a more
favorable outcome after early allo-HSCT.
Compared with the YPG, patients in the OPG did
not have significantly poorer transplantation out-
comes, including engraftment failure (P 5 .848),
SOS (P 5 .591), aGVHD (P 5 .445), cGvHD (P 5
.105), secondary graft failure after HSCT (P 5 .754),
and time to platelet engraftment (P5 .770). Moreover,
time to neutrophil engraftment was faster in the OPGTable 5. Prognostic Factors on Survival in Patients >40 years old
Factor No. of patients
Female versus male 29 versus 28
No prior IST versus prior IST 32 versus 25
Age at allo-HSCT >40 and #50 yr versus >50 yr 41 versus 16
Time from Dx to allo-HSCT #6 mo versus >6 mo 30 versus 27
Sibling donor versus others 43 versus 14
ABO compatible versus incompatible 29 versus 28
HLA full match versus mismatch 49 versus 8
Others versus female donor-to-male recipient 43 versus 14
ECOG performance status at allo-HSCT; #1 versus >1 46 versus 11
Prior PRC transfusion #12 units versus >12 units 33 versus 24
Prior PC transfusion #86 units versus >86 units 28 versus 29
Conditioning without versus with TBI 50 versus 7
Conditioning with versus without ATG/ALG 41 versus 16
Cy-ATG/ALG conditioning versus other 41 versus 16
BM as a stem cell source versus others 42 versus 15
Infused CD34 infusion >3 versus #3 (106/kg) 34 versus 23
5YSR indicates 5-year survival rate; HR, hazard ratio; CI, confidence interval;
stem cell transplantation; Dx, diagnosis; ECOG, Eastern Cooperative Oncol
body irradiation; ATG, antithymocyte globulin; ALG, antilymphocyte globulin;(P 5 .009), suggesting that allo-HSCT can be per-
formed in older patients without additional risks of
poorer transplantation outcomes. A previous study,
however, found that GVHD was significantly more
frequent in older than in younger patients [11].
Age was less significant in patients under 50 years
old, with 5YSRs similar in the YPG and in patients
\50 years in the OPG (75.0% versus 67.9%; P 5
.282). Moreover, these 2 patient cohorts had similar
5YSRs after transplantation from MRDs (82.5% ver-
sus 70.7%; P 5 .115) and after early transplantation
\6 months after diagnosis (84.8% versus 79.1%; P 5
.361). These findings suggest that allo-HSCT can be
performed successfully in patients between 40 and 50
years of age.
Our findings on 43 patients.40 years old who un-
derwent allo-HSCT from MRDs can be compared
with those of a study reporting the outcomes of allo-
HSCT from MRDs for SAA in 23 patients .40 years
of age [13]. Median age (45.8 versus 49 years), male sex
(60% versus 52.2%), donor–recipient sex mismatchUnivariate analysis Multivariate analysis
5YSR (%) P value HR 95% CI P value
51.4 versus 59.8 .469 — — —
62.0 versus 47.2 .123 0.664 0.269-1.642 .376
76.6 versus 55.9 .007 0.307 0.126-0.748 .009
62.2 versus 48.3 .129 0.563 0.208-1.521 .257
58.5 versus 46.8 .405 — — —
56.8 versus 54.0 .830 — — —
60.0 versus 22.5 .023 0.472 0.156-1.426 .183
58.2 versus 49.7 .890 — — —
52.1 versus 70.1 .297 — — —
56.5 versus 53.3 .957 — — —
55.2 versus 54.6 .933 — — —
54.1 versus 66.7 .430 — — —
57.4 versus 53.0 .683 — — —
57.4 versus 53.0 .683 — — —
61.4 versus 33.4 .950 — — —
56.2 versus 55.3 .740 — — —
IST, immune suppression therapy; allo-HSCT, allogeneic hematopoietic
ogy Group; PRC, packed red cell; PC, platelet concentrate; TBI, total
Cy, cyclophosphamide; BM, bone marrow.
Figure 2. Overall survival. (A) Shows overall survival of all patients comparing patients age\40 years old and.40 years old. (B) Shows overall survival
of patients .40 years old comparing patients\50 years old and patients .50 years old.
1506 Biol Blood Marrow Transplant 18:1500-1508, 2012H. Kim et al.(52.5% versus 48%), major ABO mismatch (17.9%
versus 17%), and median duration of AA before allo-
HSCT (3.8 versus 3 months) were comparable, al-
though the frequencies of very severe AA (7.5% versus
65%) and history of pre-allo-HSCT IST (27.5% ver-
sus 48%) were lower in our study. The rates of neutro-
phil engraftment failure (7.5% versus 4.3%), cGVHD
(27.5% versus 26%), and overall survival rates (60.1%
at 4 years versus 65% at 10 years) were also similar.We
found, however, that the median time of neutrophil
engraftment was delayed (15 versus 24 days), and the
rates of grade II to IV aGVHD (50% versus 84.2%)
and death from infection (17.5% versus 35%) were
more frequent in the earlier report. When we com-
bined rates of death from infection, engraftment fail-
ure (6.3%), and GVHD (18.8%), the overall cause of
death would be multiorgan failure and infection,
with the actual incidence of death of infection being
similar.
Our previous report for small number of unrelated
transplantation in patients with AA without TBI
showed low cGVHD rates [14]. Also, our recentFigure 3. Overall survival in patients\50 years old comparing patients\40
transplantation from HLA-identical related donor (B), and in early transplantanationwide data on unrelated transplantation in AA
without TBI (not published yet) showed similar re-
sults. However, a Korean unrelated transplantation
trial using TBI revealed a high rate of cGVHD [15].
Therefore, we think the low proportion of TBI-
conditioning in this data resulted in low incidence of
cGVHD, although many unrelated transplantations
were included. Our cumulative incidence of GVHD
was similar with that of allo-HSCT from unrelated do-
nor in SAA patients from the Japanese Marrow Donor
Program [16]. Although there were some differences,
these 2 studies reported similar and comparable out-
comes with younger patients.
Marsh et al. [17] reported new alemtuzumab with
fludarabine and cyclophosphamide conditioning,
which enrolled 24% of patients older than 50 years.
Factors influencing overall survival were HSCT co-
morbidity 2-year index (92% with score 0-1 versus
42% with score .2; P\ .001) and age (92% for age
\50 years versus 71% .50 years; P\ .001). Seattle
data showed 65% overall survival in patients over 40
years, and our data showed similar survival betweenyears old and patients .40 years. Overall survival in all patients (A), in
tion (\6 months from diagnosis to transplantation) (C).
Figure 4. Overall survival comparing unfavorable younger patients and favorable older patients. Overall survival comparing patients who were\40
years old and underwent transplantation from an alternative donor versus patients who were.40 years old and received a transplant from a matched
sibling donor (A); comparing patients who were\40 years old and whose time from diagnosis to transplantation was.6 months versus patients who
were .40 years old and whose time from diagnosis to transplantation was\6 months (B).
Biol Blood Marrow Transplant 18:1500-1508, 2012 1507Allogeneic HSCT for .40 Year Olds with Acquired Aplastic Anemiapatients\40 years and 40 to 50 years old [13]. All these
data suggest that patients.40 years but under 50 years
old with an MRD should proceed to allo-HSCT
promptly.
The overall survival of patients.40 years old with
favorable factors (early transplantation or having
MRD) was almost identical to that of patients \40
years old with unfavorable factors (later transplanta-
tion or AD). Thus, although age is a very important
clinical factor, younger patients with other unfavorable
clinical factors may have outcomes similar to older pa-
tients, indicating that age is not the only absolute cut-
off for performing allo-HSCT in patients with AA.
This study has several limitations, including its ret-
rospective design, the small numbers of patients .40
and.50 years old, and the small numbers who under-
went allo-HSCT from ADs, numbers that may have
weakened the statistical power of this study. Although
we assessedmany risk factors, our comparison of trans-
plantation outcomes and survival between the YPG
and OPG could not consider all possible clinical con-
ditions.
In conclusion, our findings suggest that older pa-
tients with severe AA can safely undergo allo-HSCT.
Older patients withMRD should undergo allo-HSCT
as early as possible to prolong survival, especially if
they are\50 years old.ACKNOWLEDGMENT
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